Yaqrit Limited is developing a family of liver disease treatments that will transform the lives of patients around the world. It is a spinout from University College London (UCL), based on 20 years of research and development at UCL.

Their team is building end-to-end solutions for patients with advanced liver disease, built around a deep and new understanding of the role of inflammation and the body’s response to liver injury in the pathogenesis of the syndrome.